Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Store the product out of the reach of small children
These mechanisms have not been proven yet
3 In a pre-specified analysis of time to first MACE-5, a composite of all-cause death, heart attack, stroke, heart failure event or coronary revascularization, there were 44 events in the Retatrutide group versus 52 in the placebo group, yielding a hazard ratio of 0.82 (95% CI: 0.55 to 1.22)
Peak does not have FDA-approved branded options
doi: 10.1016/j.atherosclerosis.2017.04.001 131 PoulterNRPrabhakaranDCaulfieldM
US$ 27.44
US$ 28.26
US$ 27.28
